Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world adverse reaction monitoring study of apatinib in advanced malignant solid tumors
ChiCTR1800019193Phase 4Not yet recruiting
- Sponsor
- First Affiliated Hospital of Nanchang University
- Start
- Oct 2018
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Rivoceranib in Nonhematologic neoplasms, sponsored by First Affiliated Hospital of Nanchang University. Primary endpoint: Adverse events. Planned start Oct 2018; status: not yet recruiting.
02
Drugs
Rivoceranib
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on ChiCTR1800019193.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800019193.